Alpa Labs Q1 FY27: Revenue up 25% YoY; PAT falls on lower investment gains

Revenue growth above 20%Results View source PDF Explain this filing

ALPA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.4%Reaction day

₹65.90

prior close

₹65.85

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-2.5% vs market

Pharmaceuticals peers, median of 166sector-0.4%-2.0% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+0.2

15m

+0.1

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.4+0.1-2.5-0.4-2.0

Next day

-3.4+0.2-3.6-0.3-3.1

-3.9+0.6-4.5-0.5-3.4

-7.1-0.0-7.1-1.3-5.8

-4.8+0.5-5.3-0.8-4.0

-4.1+0.8-4.9-0.4-3.7

-5.4+0.6-6.0-0.9-4.5

15d

-4.4+1.3-5.7+0.0-4.5

-7.4-1.4-6.1-0.1-7.3

-12.9-0.6-12.3-2.6-10.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alpa Laboratories posted Q1 FY27 revenue from operations of Rs 2,393.05 lacs, up about 25% from Rs 1,911.07 lacs YoY. Standalone PAT fell sharply to Rs 103.84 lacs from Rs 1,177.59 lacs, mainly because other income dropped to Rs 582.93 lacs vs Rs 1,195.78 lacs due to lower unrealized gains on investments. EPS stood at Rs 0.52 vs Rs 5.60. Auditor C.H. Padliya gave an unmodified review report.

Likely market impact

Strong operating revenue growth is positive, but sharp PAT decline due to non-operating investment gains may concern investors.